BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv6.1.6//EN
X-ORIGINAL-URL:https://sites.gtiit.edu.cn/research/
X-WR-CALNAME:Research, Informatics and Graduate Studies
X-WR-CALDESC:
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-c4098249cc953bd98b54e57a1ad89d12@sites.gtiit.edu.cn
DTSTART:20211230T110000Z
DTEND:20220106T120000Z
DTSTAMP:20211210T022700Z
CREATED:20211210
LAST-MODIFIED:20211214
PRIORITY:5
TRANSP:OPAQUE
SUMMARY:Guangdong-Technion Leadership in Science and Technology Lecture by Prof. Nadir Arber
DESCRIPTION:Title\nEXO-CD24 – Promise in the Corona Age – the Road From an Idea to a Groundbreaking Reality\nNote: EXO-CD24 is an anti-coronavirus drug invented by Prof. Nadir Arber.\nSpeaker\nNadir Arber MD, MSc, MHA\nProfessor of Medicine and Gastroenterology\nYechiel and Helen Lieber Professor for Cancer Research\nHead – Health Promotion Center & Head – Integrated Cancer Prevention Center\nLanguage\nEnglish\nDate & Time\nProf. Nadir Arber will present two separate lectures with popular and scientific perspectives respectively:\n1. Popular Lecture\nDate: December 30th, 2021 (Thursday)\nTime: 19:00-20:00 (Beijing Time), 13:00-14:00 (Israel Time)\nVenue: GTIIT Auditorium\nZoom link: https://gtiit.zoom.us/j/97604389435 ( https://gtiit.zoom.us/j/97604389435 )\n2. Scientific Lecture\nDate: January 6th, 2022 (Thursday)\nTime: 19:00-20:00 (Beijing Time), 13:00-14:00 (Israel Time)\nVenue: GTIIT Auditorium\nZoom link: https://gtiit.zoom.us/j/98011243663 ( https://gtiit.zoom.us/j/98011243663 )\nAbstract\nA small but significant proportion of those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop life threatening pneumonia and a hyper-inflammatory state often referred to as the cytokine storm. A great need exists for innovative therapeutic approaches. Signal transducer CD24 is a small heavily glycosylated molecule, that is GPI anchored to the cell membrane, and plays a role in many signal transduction pathways. CD24 has been shown to play a major role in dampening inflammatory signaling via multiple mechanisms, and in particular NFĸB. We have developed exosomes over-expressing immune-checkpoint-protein CD24 [EXO CD24 (OBCTCD24 Ltd., Israel)], to treat COVID-19 induced immune hyper-activation.\nHerein, we present proof-of-concept studies that the administration of EXO CD24 targets the most important complication of Covid19 disease by inhibiting the production of cytokines and chemokines.\nBio\n\nDr. Arber, is an outstanding researcher and physician, expert in internal medicine, gastroenterology, health promotion and cancer prevention. He has changed the landscape of cancer prevention and management in Israel, by establishing the first integrated cancer prevention center at Tel Aviv Medical Center and by leading cutting-edge, out-side of the box, translational research in the field of cancer therapy. Dr. Arber’s world-wide reputation among the health care providers in Israel and in the world, based on his publications and achievements.\nNadir Arber (MD, MSc, MHA) is a full Professor of medicine and gastroenterology in Tel Aviv Medical Center and Tel Aviv University, Sackler School of Medicine. He is Yechiel and Helen Lieber Professor for Cancer Research. He had graduated medical school in Hadassah, Jerusalem, in 1987 (graduating Magna Cum Laude). He had done residency in internal medicine in Rabin Medical Center (1987-1991), and fellowship in gastroenterology in the Tel Aviv Medical Center (1991-1993). He had completed his MSc in 1990 and MBA in 1991. He also had three years of research fellowship at the Comprehensive Cancer Center at Columbia University, NY, at the laboratory of Dr. Bernard Weinstein, leader and director of the center (1993-1996).\nThe following are the milestones of his career:\nIn 1999, he was nominated to head the GI Oncology Unit at the department of gastroenterology.\nIn 2002-2008 he had headed the MD thesis committee, at Tel-Aviv University Sackler Medical School\nIn 2008 – 2014 he had headed the grants committee of the Sackler School of Medicine in Tel Aviv University.\nIn 2006, he established the unique Integrated Cancer Prevention Center at the Tel Aviv Medical Center.\nfrom 2010-2017 he became the director of the cancer research center of Tel Aviv University.\nSince 2011 he is the chief of the Djerassi-Ellias oncology center.\nIn 2014-2017 he established the Dotan hemato-oncology center in Tel Aviv University.\nIn 2014 he was the president elect of the Israeli society of gastroenterology and hepatology.\nIn 2015-2017 he served as the president of the Israeli society of gastroenterology and hepatology.\nIn 2018 he was chosen to lead the cancer prevention section at the European Society of Medical Oncology (ESMO)\nMore details related to Prof. Nadir Arber and EXO-CD24 please click the links below:\n1.https://ini.comtecmed.com/dr-nadir-arber/ ( https://ini.comtecmed.com/dr-nadir-arber/ )\n2.https://mfa.gov.il/mfa/innovativeisrael/sciencetech/pages/pm-netanyahu-meets-with-prof–nadir-arber,-director-of-the-research-project-on-developing-an-anti-coronavirus-drug-8-februa.aspx ( https://mfa.gov.il/mfa/innovativeisrael/sciencetech/pages/pm-netanyahu-meets-with-prof--nadir-arber,-director-of-the-research-project-on-developing-an-anti-coronavirus-drug-8-februa.aspx )\n \n
URL:https://sites.gtiit.edu.cn/research/events/20211230/
ORGANIZER;CN=RIGS Office:MAILTO:rigs@gtiit.edu.cn
CATEGORIES:Lecture Series
LOCATION:GTIIT Auditorium
ATTACH;FMTTYPE=image/png:https://sites.gtiit.edu.cn/research/wp-content/uploads/sites/2/2021/12/Lecture-Banner-3.png
END:VEVENT
END:VCALENDAR